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Abstract
Semaphorin 4D (Sema4D/CD100) is a 150-kDa transmembrane glycoprotein expressed by platelets and T-cells. When these
cells are activated, Sema4D is cleaved proteolytically, generating a biologically active 120-kDa fragment (soluble Sema4D)
capable of targeting receptors on platelets, B-cells, endothelial cells and tumor cells. However, its plasma levels and
significance in heart failure (HF) have not been reported. In this study, we established an ELISA and detected soluble
Sema4D in human plasma. In healthy controls, plasma Sema4D levels were higher in men than women (5.1563.30 ng/mL,
n = 63, vs. 4.1962.39 ng/mL, n = 63, P,0.05). In HF patients, plasma Sema4D levels were significantly higher than those in
healthy controls (8.9465.89 ng/mL, n = 157 vs. 4.6762.99 ng/mL, n = 126, P,0.0001) with the highest levels being in HF
patients with diabetes mellitus (DM) (10.4565.76 ng/mL, n = 40). We also found that there was a higher percentage of
Sema4Dhigh CD3+ (P,0.01), CD4+ (P,0.001), and CD8+ (P,0.01) T-cells in samples from HF patients, but no changes in
Sema4D expression levels in B cells and platelets. Therefore, our investigation shows that plasma Sema4D levels are
increased in HF patients, especially in those who also have diabetes. There was an accompanying increase in the
Sema4Dhigh population of T-cells, suggesting a potential role of these T-cells in heart failure.
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Introduction
Sema4D (or CD100) is a 150-kDa type I integral membrane
glycoprotein and a member of the class IV semaphorin family. It
was first reported to be expressed on T cells where it supports B
cell development by binding to CD72, a low affinity receptor
associated with the protein tyrosine phosphatase SHP-1 [1].
Subsequent studies show that Sema4D participates in axon
guidance [2,3,4,5], angiogenesis [6,7,8] and tumor progression
[6,9,10], and that these events are mediated by a high affinity
receptor, plexin B1, and possibly plexin B2 [11]. Most recently, we
have identified Sema4D on platelets and shown that it participates
in thrombus formation in vivo by reinforcing collagen-initiated
platelet activation [12,13].
Sema4D cleavage at a juxtamembrane site generates a 120-kDa
soluble exodomain fragment capable of binding to and activating
its receptors. After being shed from blood cells, soluble Sema4D
can remain in the circulation, although its half-life is unknown.
Early studies showed that Sema4D was spontaneously shed from
T-cells by proteolytic enzymes and that the shed fragment can
affect immune cell migration, CD40-induced B-cell proliferation,
and immunoglobulin and cytokine production
[14,15,16,17,18,19]. Our previous studies on platelets [12] showed
that activated platelets also shed Sema4D and that the rate of
shedding is relatively slow compared to platelet aggregation,
requiring nearly 30 min to reach completion. The shedding is
blocked by metalloproteinase inhibitors and abolished in mouse
platelets that lack the metalloproteinase ADAM17 (TACE). Mice
lacking Sema4D exhibit delayed arterial occlusion after vascular
injury. In separate studies, MT1-MMP (membrane-type-1 matrix
metalloproteinase) has been identified as a second protease
capable of cleaving the Sema4D extracellular domain. This
process has been proposed to play a role in controlling tumor-
induced angiogenesis [20].
In addition to its role in supporting platelet activation and B-cell
development, Sema4D may participate in pathological processes.
As reviewed by Ch’ng and Kumanogoh [6], several studies have
described a role for Sema4D and plexin-B1 in tumor progression,
including soft tissue sarcomas, B-cell chronic lymphocytic leuke-
mia, renal cell carcinoma, breast and ovarian carcinomas, prostate
adenocarcinoma, and pancreatic cancer. Sema4D or CD72 have
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also been reported to play a role in systemic sclerosis [21],
experimental autoimmune encephalomyelitis [22], experimental
crescentic glomerulonephritis [23], immune complex glomerulo-
nephritis [24], and allergy [25]. Deletion of Sema4D in mice
protects against atherosclerosis by attenuating platelet hyperactiv-
ity in the setting of hyperlipidemia [26] or by reducing intimal
neovascularization [27]. Most recently, it was reported that
Sema4D expression by osteoclasts suppresses bone formation
[28] and that Sema4D indirectly regulates bone resorption via its
effect on reproductive function [29].
Heart failure (HF) is a disease with high mortality and
morbidity. The underlying disease mechanisms are complex and
may involve a variety of structural and biological alterations that
directly or indirectly impair cardiac function [30,31]. The role of
inflammation in the pathogenesis of heart failure is thought to
involve a variety of cytokines as well as leukocytes, platelets, tissue
macrophages and endothelial cells [32,33]. Additional factors may
include blood coagulation and rheological abnormalities, activa-
tion of the neuroendocrine system, and platelet abnormalities [34].
When heart failure is complicated with diabetes mellitus (DM), the
prognosis is poor due to the metabolic impact of the underlying
insulin resistance and hyperglycemia, which are associated with
diastolic dysfunction and reduced stress tolerance [35].
Since soluble Sema4D can potentially affect both the immune
and cardiovascular systems, we hypothesized that circulating
Sema4D levels may be altered in HF patients. We also asked
whether the concurrent presence of DM alters soluble Sema4D
levels in HF patients. To test this hypothesis, we developed a new
ELISA that detected soluble Sema4D in human plasma. The
results showed a significant increase in plasma Sema4D levels in
HF patients with the highest levels being in patients with both
heart failure and diabetes.
Materials and Methods
Study Population
This study was approved by the ethics committees at the First
and the Second Affiliated Hospitals, Soochow University, and the
First People’s Hospital of Yancheng City. All participants gave
written informed consent. A total of 157 HF patients from 3
hospitals in China were included. These patients were hospitalized
for symptoms of heart failure such as fatigue, shortness of breath,
and edema at rest or with exercise (New York Heart Association
[NYHA] functional classes II, III, or IV). Some patients were
previously diagnosed with heart failure and rehospitalized for
acute decompensation. The mean ejection fraction in these HF
patients was 48.1617.9%, and the mean ejection fractions of
patients with NYHA class II, III, and IV were 52.9619.1,
48.4617.1, and 44.5617.9%, respectively. Patients with chronic
obstructive lung disease, congenital heart disease, and cancer were
excluded. In addition, 126 healthy subjects, who underwent
routine medical check-ups at the hospitals and had no histories of
cardiovascular disease, were also included. All participants were
ethnic Han Chinese, the predominant population in China.
Clinical Diagnosis
As described in our previous study [36], paper and electronic
medical records were reviewed to obtain information on medical
history, clinical examination, electrocardiography (ECG), echo-
cardiography, chest X-ray, and other laboratory tests of the
patients. Cardiac arrhythmia was confirmed by ECG or 24-hour
Holter monitoring. Valvular heart disease was confirmed by
echocardiography. As part of routine practice, all patients
underwent evaluation for heart failure diagnosis and determina-
tion of disease severity by clinical history and laboratory tests
including ECG. The diagnosis of heart failure and the underlying
pathogenesis were determined by the cardiologists responsible for
the patient care. Each patient was assigned a functional class based
on the NYHA classification. Most HF patients were treated with
diuretics, angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and b-blockers, according to clinical manage-
ment guidelines.
Blood Sample Collection
Peripheral venous blood was drawn into anticoagulanted tubes,
as described previously [36]. Plasma samples were prepared by
centrifugation at 3,000 g for 10 min, aliquoted, and either used
immediately or stored at 280uC for further use within 6 months.
ELISA Assay
Recombinant soluble human Sema4D was prepared as
described [37] with the following modifications. Briefly, plasmid
pSecTag2B expressing the human Sema4D extracellular domain
was transfected into HEK293T cells using Lipofectamine 2000
(Life Technologies). After 4 hours, fresh medium was added and
the transfected cells were cultured for 3 days. Supernatants were
collected and His-tagged protein in the supernatants was purified
using TALON Metal Affinity Resin (Clontech). The supernatants
were incubated with the resin for 20 min at room temperature and
His-tagged protein was allowed to bind the resin. After washing
with a buffer (300 mmol/L sodium chloride, 50 mmol/L sodium
phosphate, 10 mmol/L imidazole), the resin was packed in a
column. Proteins were eluted from the column with the same
buffer containing 200 mmol/L imidazole and then dialyzed
against phosphate buffered saline (PBS). Purified proteins were
characterized by SDS-PAGE gel, quantified using a Bradford
protein assay (Bio-Rad), and then used as a standard in the
following ELISA.
A sandwich ELISA was developed to detect soluble Sema4D in
human plasma [38]. The purified recombinant Sema4D was used
to generate monoclonal antibodies in mice. Based on an epitope
analysis, one antibody was selected as a coating antibody (#4,
IgG1) and another as a detecting antibody (#3, IgG1) [39]. Plates
(96-wells; Corning) were coated with antibody #4 (10 mg/mL,
100 mL/well) in 50 mmol/L Na2CO3-NaHCO3, pH 9.6 at 4uC
overnight. Wells were then blocked with 3% newborn calf serum
in PBS for 2 hours. Samples and Sema4D standards were added
and incubated for 1 hour at room temperature. After washing with
a buffer (0.1% Tween-20 in PBS), HRP (horseradish peroxidase)-
conjugated detecting antibody in 3% newborn calf serum in PBS
(100 mL/well) was added and incubated at room temperature for 1
hour. One-step ultra TMB (3, 39, 5, 59-Tetramethylbenzidine)-
substrate (Pierce) was added to the wells and incubated for 30 min
in dark. Absorbance was measured at 450 nm by a plate-reader
(Spectra Max M5, Molecular Devices).
The stability of soluble Sema4D in plasma samples was tested as
described previously [40]. Pooled human plasma from 20
individuals with EDTA as an anticoagulant was measured for
soluble Sema4D after being stored at 4uC for different time
periods (0, 8, 12, 24, 48, and 72 h) or frozen and thawed for
several cycles. All samples tested had similar Sema4D levels as that
of pooled fresh sample (data not shown). Therefore, soluble
Sema4D in plasma was stable up to 72 h in 4uC storage condition
or 5 cycles of freezing and thawing. As a practical matter for the
studies included in this manuscript, plasma Sema4D levels were
either determined immediately or after storage at 280uC for no
more than 6 months.
Soluble Sema4D in Heart Failure
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Platelet Aggregation and Western Blot
Venous blood from healthy donors was anti-coagulated 1:5 with
ACD (65 mmol/L Na3Citrate, 70 mmol/L citric acid,
100 mmol/L dextrose, pH 4.4) and centrifuged at 900 rpm for
20 min to obtain platelet-rich plasma (PRP) [13]. Gel-filtered
platelets were prepared as described previously [41]. Platelets
(26108/mL) were pre-incubated with or without 17b-estradiol for
3 min and stimulated with collagen or ADP at 37uC under
constant stirring at 1,000 rpm. Platelet aggregation was monitored
in a lumi-aggregation meter (Chrono-Log) for 8 min and the
reaction was stopped by adding cold RIPA (Radio Immunopre-
cipitation Assay) buffer with protease inhibitors (Roche). Platelet
lysates were boiled for 10 min and proteins were separated on
10% SDS-PAGE gels, transferred to a polyvinylidenefluoride
Figure 1. Establishment of a sandwish ELISA to measure soluble Sema4D in human plasma. A. pSecTag2B plasmid containing His-tagged
Sema4D coding sequence for amino acids 1–734 was expressed in HEK293T cells. His-tagged Sema4D in the conditioned medium was purified by
affinity chromatography. The recombinant Sema4D (rSema4D) migrated as an approximately 120-kDa protein in SDS-PAGE gel. B. An ELISA was
developed using coating antibody #4, detecting antibody #3 conjugated with HRP, and rSema4D as a standard. The standard curve was generated
under optimized conditions (capture antibody, 10 mg/mL; detection antibody, 200 ng/mL). C. Healthy donors (n = 126), who underwent routine
medical check-ups and had no medical history of cardiovascular diseases, were examined for their plasma soluble Sema4D levels as described in
Materials and Methods.
doi:10.1371/journal.pone.0064265.g001
Figure 2. Plasma Sema4D levels in different gender and age groups of healthy donors, and the effects of 17b-estradiol on Sema4D
expression in Jurkat cells and Sema4D shedding in human platelets. A. Plasma Sema4D levels in healthy males and females. B. Plasma
Sema4D levels in healthy donors of different age groups. Each box represents the median and interquartile range values. The outliers that are .1.5
the interquartile range are indicated by filled circles. The vertical bars indicate the non-outlier minimum and maximum. C. The percentages of
Sema4Dhigh Jurkat cells with or without 10 mM 17b-estradiol treatments were measured by flow cytometry. P values were obtained using ANOVA
followed by a Tukey post test. D. Gel-filtered platelets were prepared from healthy donors and pre-incubated with 0.5% DMSO (vehicle control) or
17b-estradiol (40 mM, 60 mM and 80 mM) for 3 min. Collagen (2 mg/mL) was used to induce platelet aggregation for 8 min. Platelet samples were
analyzed by Western blot using a Sema4D C-terminal antibody to visualize the Sema4D cleavage product. Data shown are representative of at least 3
independent experiments.
doi:10.1371/journal.pone.0064265.g002
Soluble Sema4D in Heart Failure
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(PVDF) membrane, and immunoblotted with a purified mouse
anti-Sema4D antibody (BD Transduction Laboratories) followed
by a goat anti-mouse IRDye 680 or 800 antibody (LI-COR
Biosciences, Lincoln, NE).
Flow Cytometry
Peripheral blood mononuclear cells (PBMCs) were isolated from
anti-coagulated blood by HISTOPAQUE-1077 (Sigma-Aldrich)
gradient centrifugation. PBMCs were double-stained using an
anti-Sema4D-PE antibody (A8, Abcam, Cambridge, UK) together
with either an anti-CD3-FITC, anti-CD4-FITC, anti-CD8-FITC,
or anti-CD19-FITC monoclonal antibody (BD Biosciences,
Erembodegem, Belgium). Jurkat cells were cultured in RPMI-
1640 medium with 10% of FBS (fetal bovine serum) (Hyclone) and
stained using an anti-CD100-PE antibody. Background fluores-
cence was determined using an isotypic antibody control (BD
Biosciences). Cells were analyzed using a flow cytometer (BD
Biosciences). Sema4D expression on platelet surface was measured
in whole blood double stained with anti-Sema4D-PE and anti-
CD41-FITC antibodies.
Statistical Analysis
The analysis was performed using SPSS (version18) and
GraphPad Prism5 software. Data are presented as mean 6 SD.
Comparisons of plasma Sema4D levels in healthy controls and
patient groups were performed using ANOVA followed by a
Tukey post test. All probabilities were 2-tailed, and p values of
,0.05 were considered statistically significant.
Table 1. Characteristics of healthy donors and HF patients.
Characteristics Control (n = 126) HF (n =157)
Age, mean (SD) 44.7 (11.9) 66.2 (14.9)
Sex, n (%)
male 63 (50) 88 (56.1)
female 63 (50) 69 (43.9)
Medical history, n (%)
Hypertension 0 (0) 94 (59.9)
Diabetes mellitus 0 (0) 40 (25.5)
Valvular heart disease 0 (0) 17 (10.8)
Cardiomyopathy 0 (0) 20 (12.7)
Coronary artery disease 0 (0) 24 (15.3)
Cardiac arrhythmia 0 (0) 18 (11.5)
Others 0 (0) 23 (14.6)
doi:10.1371/journal.pone.0064265.t001
Figure 3. Plasma soluble Sema4D levels in HF patients. A total of 157 HF patients were studied. A. Comparison of plasma Sema4D levels
between HF patients and healthy donors. B. Comparison of plasma Sema4D levels between male and female HF patients. C. Comparison of plasma
Sema4D levels in HF patients of NYHA functional classes II, III, and IV. D. Comparison of plasma Sema4D levels in HF patients of different age groups.
Each box represents the median and interquartile range values. The outliers that are .1.5 and.3 times the interquartile range are indicated by filled
circles and stars, respectively. The vertical bars indicate the non-outlier minimum and maximum. P values were obtained using ANOVA followed by a
Tukey post test.
doi:10.1371/journal.pone.0064265.g003
Soluble Sema4D in Heart Failure
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Results
ELISA Assay for Soluble Sema4D
A human recombinant Sema4D (rSema4D) extracellular
fragment containing amino acids 1–734 was expressed and
purified. On SDS-PAGE gels under reducing conditions, the
purified protein appeared as a single band of approximately
120 kDa (Figure 1A). To measure Sema4D in human plasma, an
ELISA assay was established using two monoclonal antibodies
recognizing different epitopes in the Sema4D extracellular region
[39]. The assay had a detection limit of 0.5360.03 ng Sema4D/
mL of human plasma, as determined by the average concentration
of the background x+2SD, and a linear range of 0.56–30 ng/mL
of plasma Sema4D (Figure 1B).
Figure 4. Plasma Sema4D levels in HF patients with diabetes or hypertension. A. Plasma Sema4D levels in HF patients with or without
diabetes mellitus (DM). B. Plasma Sema4D levels in HF patients with or without hypertension (HP) history. Each box represents the median and
interquartile range values. The outliers that are .1.5 and .3 times the interquartile range are indicated by filled circles and stars, respectively. The
vertical bars indicate the non-outlier minimum and maximum. P values were obtained using ANOVA followed by a Tukey post test.
doi:10.1371/journal.pone.0064265.g004
Figure 5. Sema4D expression on lymphocytes in HF patients and healthy donors. Fresh PBMCs from HF patients and healthy donors were
double-stained and analyzed by FACS. The region corresponding to lymphocytes (R1) was selected using an FSC-H/SSC-H density plot. Using an FITC-
density plot applied to the R1 region, the regions R2 and R3 corresponding to CD3+ and CD19+ cells, respectively, were defined (upper panels of 5A
and 5B). In the PE density plot (middle panels of 5A and 5B), the right region delimits CD3+ and CD19+ cells with high expression of Sema4D,
respectively. PE-conjugated IgG was used as an isotypic control. The percentage of Sema4Dhigh CD3+ cells and Sema4Dhigh CD19+ cells in healthy
donors (HD) and HF patients (HF) were analyzed (lower panels of 5A and 5B). P values were obtained using ANOVA followed by a Tukey post test.
doi:10.1371/journal.pone.0064265.g005
Soluble Sema4D in Heart Failure
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64265
Soluble Sema4D in Human Plasma
In 126 healthy individuals, plasma Sema4D levels were
4.6762.99 ng/mL (Figure 1C). There was a small but statistically
significant gender difference: levels of plasma Sema4D in men
(5.1563.30 ng/mL, n= 63) were higher than that in women
(4.1962.39 ng/mL, n= 63, P,0.05) (Figure 2A). There were no
significant age-related differences (Figure 2B).
Effect of Estradiol on Sema4D Expression and Shedding
To test the hypothesis that estrogen may influence plasma
Sema4D levels, we studied the effect of 17b-estradiol on Sema4D
expression in T cell-derived Jurkat cells. Flow cytometry showed
that Sema4D expression in Jurkat cells was decreased in the
presence of 17b-estradiol (P,0.001) (Figure 2C). We also
examined Sema4D shedding by human platelets [12] and found
that pre-incubation of platelets with 17b-estradiol markedly
inhibited Sema4D shedding induced by collagen (Figure 2D).
These results suggest that estrogen and its derivatives may inhibit
both Sema4D expression and shedding.
Increased Plasma Sema4D Levels in HF Patients
Next, we measured plasma Sema4D levels in HF patients. The
main characteristics of the 157 HF patients in this study are
summarized in Table 1. The levels of plasma Sema4D in HF
patients (8.9465.89 ng/mL) were significantly higher than those
of healthy controls (4.6762.99 ng/mL) (P,0.0001) (Figure 3A). In
contrast to the healthy controls, there was no significant gender
difference in plasma Sema4D levels in HF patients
(9.2666.35 ng/mL in males n= 88 vs. 8.5465.26 ng/mL in
females, n = 69, P.0.05) (Figure 3B). To test whether the
increased Sema4D levels correlate with the disease severity, we
grouped HF patients into three NYHA classes (class II, n = 24;
class III, n = 79; class IV, n= 46). Plasma Sema4D levels were
9.8367.07, 8.8365.39, and 8.8966.31 ng/mL, respectively.
None of these differences are statistically significant (Figure 3C;
P values .0.5). There was also no correlation between ejection
fraction and soluble Sema4D levels (analysis not shown). As in the
healthy individuals, plasma Sema4D levels did not differ in
different age groups (Figure 3D).
Increased Plasma Sema4D Levels in HF Patients with
Diabetes
DM and hypertension are known risk factors for heart failure.
We analyzed whether these risk factors correlated with the
increased plasma Sema4D levels. As shown in Figure 4A, HF
patients with diabetes (10.4565.76 ng/mL, n= 40) or without
diabetes (8.4265.87 ng/mL, n= 117) had higher plasma Sema4D
levels than healthy controls (4.6762.99 ng/mL, n= 126) (both P
values ,0.01). Levels were highest in patients with diabetes. In
contrast, levels were similar in HF patients with or without
hypertension (Figure 4B).
Increased Sema4D-positive T Cells but not B Cells or
Platelets in HF Patients
Lymphocytes and platelets [12] are the primary cells
expressing Sema4D in the hematopoietic system. We hypoth-
esized that increased plasma Sema4D levels in HF patients may
be due to increased Sema4D expression and/or shedding in
circulating lymphocytes or platelets. Interestingly, although
overall lymphocyte numbers were unaffected, the percentage
Figure 6. Sema4D expression on T cell subpopulations in HF patients and healthy donors. Fresh PBMCs from HF patients and healthy
donors were double-stained and analyzed by FACS. The region corresponding to lymphocytes (R1) was selected using an FSC-H/SSC-H density plot.
Using a FITC-density plot applied to the R1 region, the regions R4 and R5 corresponding to CD4+ and CD8+ cells, respectively, were defined (upper
panels of 6A and 6B). In the PE density plot (middle panels of 6A and 6B), the right region delimits CD4+ and CD8+ cells with high expression of
Sema4D, respectively. PE-conjugated IgG was used as an isotypic control. The percentage of Sema4Dhigh CD4+ cells and Sema4Dhigh CD8+ cells in
healthy donors (HD) and HF patients (HF) were analyzed (lower panels of 6A and 6B). P values were obtained using ANOVA followed by a Tukey post
test.
doi:10.1371/journal.pone.0064265.g006
Soluble Sema4D in Heart Failure
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of Sema4Dhigh CD3+ T-cells was significantly higher in HF
patients than healthy donors (P=0.002) (Figure 5A). Such a
difference was not observed in CD19+B cells (P=0.46) in these
two groups (Figure 5B). These results indicate that Sema4D-
positive T lymphocytes were increased in HF patients, which
may contribute to the increased plasma Sema4D levels in these
patients. We also examined T cell subpopulations and found
that Sema4D expression in both Sema4Dhigh CD4+ (P=0.0006)
(Figure 6A) and Sema4Dhigh CD8+ (P=0.015) (Figure 6B) T
cells was significantly higher in HF patients than healthy
controls.
To evaluate whether platelet Sema4D contributes to the
increased levels of soluble Sema4D in HF patients, we isolated
platelets from HF patients and health donors, and measured
surface expression of Sema4D. Platelets were double-stained with
anti-CD41 and anti-Sema4D antibodies. HF patients had slightly
higher levels of soluble Sema4Dhigh platelets than healthy
individuals (Figure 7). The difference, however, was not statisti-
cally significant (P=0.188).
Discussion
Lymphocyte and platelet activation increases Sema4D expres-
sion and subsequent proteolytic cleavage to generate soluble forms
of Sema4D [12,42]. Plasma Sema4D levels may vary under
pathological conditions. Several studies [14,17,21] have used
ELISA to measure Sema4D in human and mouse serum or cell
culture media. However, measurements made in serum samples
are potentially confounded by the release of Sema4D from
platelets ex vivo during preparation of the serum from whole blood
samples, making it difficult to use the data to interpret plasma
Sema4D levels. Here we focused on plasma Sema4D levels, which
may better reflect circulating soluble Sema4D levels in blood. We
developed an ELISA using two antibodies against different
epitopes in the Sema4D extracellular domain and detected
Sema4D in human plasma.
Unexpectedly, we found that the levels were lower in healthy
females than males, suggesting that sex hormones may affect
Sema4D expression and/or shedding. Indeed, we found that 17b-
estradiol, a potent estrogen derivative, inhibited Sema4D expres-
sion in T cell-derived Jurkat cells and collagen-induced Sema4D
shedding in human platelets. Possibly, estrogen and its derivatives
may inhibit Sema4D expression and shedding in vivo, resulting in
the small gender difference observed in healthy subjects.
An important finding of this study is that plasma Sema4D levels
were significantly higher in HF patients than healthy controls.
Unlike in healthy controls, we did not observe a significant gender
difference in plasma Sema4D levels in HF patients. Since plasma
Sema4D levels were significantly elevated in both male and female
HF patients, the increase may have obscured difference that
occurs in healthy adults. Alternatively, the inhibitory effect of
female hormones on Sema4D expression and/or shedding may be
counter-balanced by other neural hormonal changes that may
occur in HF patients.
To understand the mechanism underlying the elevated plasma
Sema4D levels in HF patients, we analyzed platelets and T cells,
two major cellular sources of Sema4D in blood. By flow
cytometry, we did not find significant differences in platelet
Sema4D levels between HF patients and healthy controls,
suggesting that other blood cells, possibly T cells, are the primary
source of increased plasma Sema4D levels in HF patients. Indeed,
we found that HF patients had a significantly increased T cell
subpopulation that was Sema4D positive, which included
Sema4Dhigh CD3+, Sema4Dhigh CD4+, and Sema4Dhigh CD8+
cells. In contrast, we did not detect major differences in CD19+ B
cell population between HF patients and healthy controls. These
results indicate that a subpopulation of Sema4D-positive T cells
was increased in HF patients and may contribute to the high levels
of Sema4D in patients’ plasma. Further investigation on the
relation of Sema4Dhigh T cells with markers of inflammation and
cytokine levels in heart failure would help understand the
mechanism of this cardiovascular disorder.
Sema4D is an integral membrane protein. Metalloproteinase
ADAM17 and MT1-MMP have been identified to shed Sema4D
from the surface of platelets and cancer cells [12,20]. ADAM17 is
known to cleave its substrates TNFa receptor and L-selectin in T
cells [43]. Similarly, MT1-MMP is also expressed in T cells [44].
In platelets, ADAM17 is the primary enzyme responsible for
Sema4D shedding, as indicated by the lack of Sema4D shedding
in the absence of ADAM17 [12]. Studies have shown that
ADAM17 and MT-MMP1 expression is up-regulated in cardio-
myocytes and PBMCs in patients with heart disease [45], [46],
[47]. It is possible that increased activities of ADAM17 and/or
MT1-MMP promoted Sema4D shedding from T cells in HF
Figure 7. Sema4D expression on platelet surface in HF patients
and healthy donors. Whole blood diluted 1:20 in Tyrode buffer was
double-stained and analyzed by FACS. Using a FITC-density plot applied
to the R1 region, the region R2 corresponding to platelets was defined
(upper panels). In the PE density plot (middle panels), the right region
delimits platelets with high expression of Sema4D in healthy individuals
or HF patients. PE-conjugated IgG was used as an isotypic control. The
percentage of Sema4Dhigh platelets in HF patients and healthy donors
(HD) was presented in dotted diagrams (lower panel). P values were
obtained using ANOVA followed by a Tukey post test.
doi:10.1371/journal.pone.0064265.g007
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patients, thereby contributing to the elevated levels of plasma
Sema4D.
Another notable finding of this study is that plasma Sema4D
levels in HF patients with diabetes were even higher than those in
HF patients without diabetes. Diabetes is a chronic progressive
metabolic disease. Two Sema4D receptors, plexins B1 and B2,
have been identified in pancreatic epithelial ducts of mouse
embryos. Their expression appeared to co-localize with both
insulin-producing b cells and glucagon-producing a cells [48].
Similar findings were reported in human pancreas, where
Sema4D-positive infiltrating lymphocytes interacted with plexin
B1-positive tumor cells in pancreatic ducts [49]. It is possible that
in HF patients an increased Sema4D-positive T cell subpopulation
may target pancreatic cells and reduce insulin production. In
addition, Sema4D may exacerbate vascular complications in DM
patients by interacting with endothelial cells to promote vascular
inflammation, endothelial dysfunction, microthrombus formation
and atherosclerosis [50].
In summary, we report here that soluble Sema4D is present in
the plasma of healthy individuals and that the level was increased
in HF patients, especially in those with concurrent diabetes. The
increase in plasma Sema4D levels was associated with an increase
in Sema4D-positive T-cells in HF patients. These results suggest a
possible mechanism, by which plasma soluble Sema4D and/or
Sema4D-positive T-cells may contribute to the development and/
or progression of heart failure and diabetes in patients. Our study
has its limitations because of its retrospective nature and a
relatively small set of patient samples. Conversely, HF and
diabetes may result in high levels of plasma Sema4D, which in
turn may exacerbate HF and diabetes. Our findings should
encourage future studies in animal models and with larger cohorts
of patients to understand the role of Sema4D in heart failure and
diabetes.
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